The Safety and Tolerability of Pirfenidone for Bronchiolitis Obliterans Syndrome After Hematopoietic Cell Transplantation

Trial Profile

The Safety and Tolerability of Pirfenidone for Bronchiolitis Obliterans Syndrome After Hematopoietic Cell Transplantation

Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Mar 2018

At a glance

  • Drugs Pirfenidone (Primary)
  • Indications Bronchiolitis obliterans
  • Focus Adverse reactions
  • Acronyms STOP-BOS
  • Most Recent Events

    • 15 Mar 2018 Planned End Date changed from 31 Mar 2021 to 31 Mar 2020.
    • 15 Mar 2018 Planned primary completion date changed from 31 Mar 2020 to 31 Jan 2020.
    • 01 Mar 2018 Planned End Date changed from 31 Dec 2020 to 31 Mar 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top